Calliditas Therapeutics, a Swedish biotech developing therapies for orphan kidney and liver diseases, raised $90 million in an upsized IPO by offering 4.6 million ADS equivalents at $19.50 per ADS. It originally planned to raise $75 million by offering 3.8 million ADS equivalents. Its last close on the Nasdaq Stockholm (CALTX) was SEK 93.90 per common share, or $20.40 per ADS ($1 = SEK 9.2047). Calliditas now commands a fully diluted market value of $467 million.
Calliditas Therapeutics plans to list on the Nasdaq under the symbol CALT. Citi, Jefferies and Stifel acted as lead managers on the deal.
